Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueInventory Average

RedHill Biopharma (RDHL) Net Margin (2016 - 2023)

Historic Net Margin for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to 3280.68%.

  • RedHill Biopharma's Net Margin rose 32446700.0% to 3280.68% in Q2 2023 from the same period last year, while for Dec 2024 it was 3280.68%, marking a year-over-year increase of 33824700.0%. This contributed to the annual value of 0.0% for FY2024, which is 3662500.0% down from last year.
  • According to the latest figures from Q2 2023, RedHill Biopharma's Net Margin is 3280.68%, which was up 32446700.0% from 220.03% recorded in Q1 2023.
  • Over the past 5 years, RedHill Biopharma's Net Margin peaked at 3280.68% during Q2 2023, and registered a low of 658.08% during Q4 2021.
  • For the 5-year period, RedHill Biopharma's Net Margin averaged around 368.88%, with its median value being 67.81% (2020).
  • As far as peak fluctuations go, RedHill Biopharma's Net Margin crashed by -14921500bps in 2021, and later soared by 32446700bps in 2023.
  • RedHill Biopharma's Net Margin (Quarter) stood at 744.47% in 2019, then plummeted by -91bps to 70.29% in 2020, then plummeted by -1036bps to 658.08% in 2021, then increased by 17bps to 543.22% in 2022, then surged by 704bps to 3280.68% in 2023.
  • Its Net Margin was 3280.68% in Q2 2023, compared to 220.03% in Q1 2023 and 543.22% in Q4 2022.